Jaguar Health, Inc. (NASDAQ:JAGX)

PRESS RELEASE

published on 06/17/2025 at 15:00, 7 months 13 days ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present virtually at Emerging Growth Conference on June 18, 2025. Focus on pharmaceuticals from rainforest plants for gastrointestinal distress. Notable brands: Mytesi, Napo Therapeutics

Pharmaceuticals Gastrointestinal Distress Jaguar Health Emerging Growth Conference Mytesi
BRIEF

published on 06/11/2025 at 16:05, 7 months 19 days ago

Jaguar Health lance une étude sur le médicament Canalevia-CA1 chez le chien

Crofelemer Jaguar Health Canalevia-CA1 Approbation De La FDA Diarrhée Du Chien
BRIEF

published on 06/11/2025 at 16:05, 7 months 19 days ago

Jaguar Health Launches Study for Canalevia-CA1 Drug in Dogs

Crofelemer FDA Approval Jaguar Health Canalevia-CA1 Dog Diarrhea
PRESS RELEASE

published on 06/11/2025 at 16:00, 7 months 19 days ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Jaguar Health, Inc. announces goals to expand crofelemer usage from chemotherapy-induced to general diarrhea treatment in dogs. Research studies and partnerships in progress

Crofelemer Jaguar Health Partnerships Dogs Diarrhea Treatment
BRIEF

published on 06/09/2025 at 22:20, 7 months 21 days ago

Jaguar Health to Discuss Phase 3 Trial Results in Virtual Chat

Jaguar Health Phase 3 Trial Breast Cancer Orphan Diseases FDA Meeting
BRIEF

published on 06/09/2025 at 22:20, 7 months 21 days ago

Jaguar Health discutera des résultats de l'essai de phase 3 lors d'une discussion virtuelle

Jaguar Health Essai De Phase 3 Cancer Du Sein Maladies Orphelines Réunion De La FDA
PRESS RELEASE

published on 06/09/2025 at 22:15, 7 months 21 days ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners’ Spring 2025 Spotlight Series
Jaguar Health, Inc. to discuss Phase 3 OnTarget trial results for metastatic breast cancer subgroup. Focus on orphan population and expanded access program. Virtual fireside chat with CEO Lisa Conte on June 10, 2025

Jaguar Health Phase 3 OnTarget Trial Virtual Fireside Chat Metastatic Breast Cancer Orphan Population
BRIEF

published on 06/09/2025 at 15:05, 7 months 21 days ago

Jaguar Health Discusses Crofelemer Pathway with FDA

Crofelemer FDA Approval Orphan Drug Designation Metastatic Breast Cancer Expanded Access Program
BRIEF

published on 06/09/2025 at 15:05, 7 months 21 days ago

Jaguar Health discute du protocole Crofelemer avec la FDA

Crofelemer Désignation De Médicament Orphelin Approbation De La FDA Cancer Du Sein Métastatique Programme D'accès Élargi
PRESS RELEASE

published on 06/09/2025 at 15:00, 7 months 21 days ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer
Jaguar Health's Napo Pharmaceuticals shares plans to seek approval for crofelemer in cancer therapy-related diarrhea for metastatic breast cancer patients. Key discussions with FDA highlighted in Type C Meeting

Napo Pharmaceuticals Crofelemer Jaguar Health Cancer Therapy Metastatic Breast Cancer

Published on 01/31/2026 at 03:15, 7 hours 10 minutes ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 8 hours 5 minutes ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 8 hours 45 minutes ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 10 hours 25 minutes ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 11 hours 25 minutes ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 02:45, 7 hours 39 minutes ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 12 hours 25 minutes ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 14 hours 14 minutes ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 20:09, 14 hours 15 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches
Published on 01/30/2026 at 20:07, 14 hours 17 minutes ago

Aroundtown SA successfully issued AUD 600 million bonds in two tranches

View all EQS

Published on 01/30/2026 at 18:40, 15 hours 45 minutes ago

ICADE - Bilan semestriel du contrat de liquidite
Published on 01/30/2026 at 18:01, 16 hours 24 minutes ago

Emova Group - Résultats annuels 2024/25
Published on 01/30/2026 at 17:45, 16 hours 40 minutes ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 17:45, 16 hours 40 minutes ago

Schneider Electric lance une augmentation de capital réservée aux salariés
Published on 01/30/2026 at 08:30, 1 day 1 hour ago

Claude Bernard lance Senior+, un assistant IA conçu pour améliorer la prise en charge des patients les plus âgés

View all LES ECHOS COMFI WIRE

News